Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine falls 29% on Phase IIb tardive dyskinesia miss

This article was originally published in Scrip

Executive Summary

Neurocrine Biosciences fell 29% in after-hours trading on 9 September after the company said its 50mg dose of NBI-98854 for the treatment of tardive dyskinesia missed the six-week primary endpoint in a Phase IIb clinical trial, but a 100mg dose provided statistically significant improvements without worsening patients' schizophrenia after just two weeks of therapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022677

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel